Shire PLC (SHP) Receives “Buy” Rating from Kepler Capital Markets
Kepler Capital Markets reissued their buy rating on shares of Shire PLC (LON:SHP) in a report released on Friday morning. Kepler Capital Markets currently has a GBX 4,600 ($60.50) target price on the biopharmaceutical company’s stock.
A number of other brokerages have also recently issued reports on SHP. Beaufort Securities reiterated a long term buy rating and set a GBX 4,900 ($64.45) price objective (down from GBX 6,200 ($81.55)) on shares of Shire PLC in a report on Friday, August 4th. Shore Capital reiterated a buy rating on shares of Shire PLC in a report on Monday, November 13th. reduced their price objective on shares of Shire PLC from GBX 4,480 ($58.92) to GBX 4,050 ($53.27) and set a hold rating for the company in a report on Tuesday, October 31st. Citigroup Inc. reiterated a buy rating and set a GBX 6,300 ($82.86) price objective on shares of Shire PLC in a report on Tuesday, August 22nd. Finally, Jefferies Group LLC reduced their price objective on shares of Shire PLC from GBX 5,600 ($73.66) to GBX 5,250 ($69.05) and set a buy rating for the company in a report on Monday, August 7th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of GBX 5,358.82 ($70.48).
Shares of Shire PLC (LON:SHP) traded down GBX 65.50 ($0.86) during midday trading on Friday, hitting GBX 3,678.50 ($48.38). 5,224,379 shares of the stock were exchanged, compared to its average volume of 2,540,000. Shire PLC has a 52-week low of GBX 3,435.50 ($45.19) and a 52-week high of GBX 5,067 ($66.64).
In other Shire PLC news, insider Flemming Ornskov purchased 8,400 shares of the stock in a transaction dated Tuesday, August 22nd. The shares were bought at an average price of GBX 3,665 ($48.20) per share, with a total value of £307,860 ($404,919.11). Also, insider Anne Minto purchased 190 shares of the stock in a transaction dated Friday, September 29th. The stock was acquired at an average cost of GBX 3,785 ($49.78) per share, for a total transaction of £7,191.50 ($9,458.77).
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.